The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Garrido, MM (Author) Other; Ribeiro, R (Author) Other; Pinheiro, LC (Author) Other; Holdenrieder, S (Author) Other; guimaraes, jt (Author) FMUP

Journal

Title: Clinical Chemistry and Laboratory Medicine

Vol. 59

Pages: 1869-1877

ISSN: 1434-6621

Publisher: Walter De Gruyter

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00V-EHA

DOI: 10.1515/cclm-2021-0554

Abstract (EN): Objectives: To evaluate the diagnostic performance of the prostate health index (PHI) and of the percentage of [-2] proPSA (%[-2]proPSA) calculated with total and free PSA from non-Beckman Coulter manufacturers (Roche and Abbott), and compare it with the fully Beckman Coulter [-2] proPSA derivatives. Methods: In this study, 237 men (PSA: 2-10 mu g/L) scheduled for prostate biopsy were enrolled. %[-2]proPSA and PHI were calculated with total and free PSA from three manufacturers. Beckman Coulter PSA and [-2]proPSA were performed on the Access 2 analyzer (Hybritech calibration). Roche PSA was performed on the cobas e411 and the Abbott PSA on the Architect i2000sr. Statistical analysis was performed, considering prostate cancer (PCa) as the outcome. Results: Univariate analysis showed that all indices were predictors of cancer, irrespective of the manufacturer (p<0.001). The AUC was similar for all manufacturers, both for %[-2]proPSA (Beckman Coulter: 0.756; Roche: 0.770; Abbott: 0.756) and PHI (Beckman Coulter: 0.776; Roche: 0.785; Abbott: 0.778). When considering the cutoffs that allowed 90% sensitivity, [-2]proPSA derivatives calculated with Roche and Abbott PSA had similar specificities and predictive values when compared to Beckman Coulter. The percentage of missed cancers (8-9%) was the same between manufacturers. The percentage of spared biopsies was significantly higher with Roche's PHI (21.0%) and Abbott's PHI (20.6%) than with Beckman Coulter's PHI (17.2%). Conclusions: In the PSA range between 2 and 10 mu g/L, [-2] proPSA derivatives maintain their diagnostic performance in PCa detection when calculated with PSA from Roche and Abbott. This can lead to a broader implementation of these indices in clinical laboratories worldwide.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9